English  |  正體中文  |  简体中文  |  Items with full text/Total items : 17933/22952 (78%)
Visitors : 7332272      Online Users : 384
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version
    Please use this identifier to cite or link to this item: https://ir.csmu.edu.tw:8080/ir/handle/310902500/11895


    Title: Increased plasma levels of urokinase plasminogen activator and matrix metalloproteinase-9 in nonsmall cell lung cancer patients.
    Authors: Yang SF;Hsieh YS;Lin CL;Hsu NY;Chiou HL;Chou FP;Chu SC
    Contributors: 中山醫學大學
    Keywords: Matrix metalloproteinase-9;Urokinase plasminogen activator;Nonsmall cell lung cancer
    Date: 2005-04
    Issue Date: 2015-08-03T08:11:38Z (UTC)
    ISSN: 0009-8981
    Abstract: BACKGROUND:
    The involvements of matrix metalloproteinase-9 (MMP-9) and urokinase plasminogen activator (uPA) in the pathogenesis of various types of lung cancers have been established. The aim of the present study was to determine the concentrations of MMP-9 and uPA in the plasma of nonsmall cell lung cancer (NSCLC) patients.
    METHODS:
    Gelatin zymography and ELISA were used to measure MMP-9 and uPA concentrations, respectively, in 90 NSCLC patients and 50 control subjects.
    RESULTS:
    Compared with that of control subjects, MMP-9 and uPA levels were significantly higher in the plasma of NSCLC patients (P<0.001 and P<0.01, respectively). Further statistical analysis for clinic pathological parameters revealed that MMP-9 and uPA levels were significantly increased in patients with metastasis (P<0.01 and P<0.05, respectively). Furthermore, the MMP-9 level was significantly different between smokers and nonsmokers (P<0.05) while uPA levels varied between histological types (P<0.05).
    CONCLUSIONS:
    Background

    The involvements of matrix metalloproteinase-9 (MMP-9) and urokinase plasminogen activator (uPA) in the pathogenesis of various types of lung cancers have been established. The aim of the present study was to determine the concentrations of MMP-9 and uPA in the plasma of nonsmall cell lung cancer (NSCLC) patients.

    Methods

    Gelatin zymography and ELISA were used to measure MMP-9 and uPA concentrations, respectively, in 90 NSCLC patients and 50 control subjects.

    Results

    Compared with that of control subjects, MMP-9 and uPA levels were significantly higher in the plasma of NSCLC patients (P<0.001 and P<0.01, respectively). Further statistical analysis for clinic pathological parameters revealed that MMP-9 and uPA levels were significantly increased in patients with metastasis (P<0.01 and P<0.05, respectively). Furthermore, the MMP-9 level was significantly different between smokers and nonsmokers (P<0.05) while uPA levels varied between histological types (P<0.05).

    Conclusions

    Plasma MMP-9 and uPA might play an important role in the metastasis of NSCLC by involvement in the processes of invasion and metastasis.
    URI: https://ir.csmu.edu.tw:8080/ir/handle/310902500/11895
    http://dx.doi.org/10.1016/j.cccn.2004.11.011
    Relation: Clin Chim Acta. 2005 Apr;354(1-2):91-9.
    Appears in Collections:[醫學檢驗暨生物技術學系暨碩士班] 期刊論文

    Files in This Item:

    File Description SizeFormat
    index.html0KbHTML394View/Open


    SFX Query

    All items in CSMUIR are protected by copyright, with all rights reserved.


    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback